Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 1
1949 2
1950 1
1951 8
1952 11
1953 5
1954 2
1955 2
1956 3
1957 1
1958 2
1959 1
1960 2
1961 1
1962 2
1963 3
1964 5
1965 2
1966 5
1967 3
1968 4
1969 9
1970 7
1971 13
1972 8
1973 4
1974 12
1975 5
1976 10
1977 18
1978 17
1979 29
1980 39
1981 26
1982 20
1983 19
1984 26
1985 20
1986 38
1987 30
1988 53
1989 41
1990 44
1991 41
1992 49
1993 58
1994 46
1995 54
1996 46
1997 38
1998 47
1999 57
2000 60
2001 63
2002 76
2003 52
2004 80
2005 101
2006 88
2007 64
2008 91
2009 107
2010 103
2011 123
2012 94
2013 116
2014 120
2015 131
2016 138
2017 146
2018 161
2019 147
2020 156
2021 215
2022 196
2023 176
2024 97

Text availability

Article attribute

Article type

Publication date

Search Results

3,546 results

Results by year

Filters applied: . Clear all
Page 1
Amblyopia and the whole child.
Birch EE, Kelly KR. Birch EE, et al. Among authors: kelly kr. Prog Retin Eye Res. 2023 Mar;93:101168. doi: 10.1016/j.preteyeres.2023.101168. Epub 2023 Feb 1. Prog Retin Eye Res. 2023. PMID: 36736071 Free PMC article. Review.
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.
Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, Cho S, Wu Y, Punnett A, Dave H, Henderson TO, Hoppe BS, Charpentier AM, Keller FG, Kelly KM. Castellino SM, et al. Among authors: kelly km. N Engl J Med. 2022 Nov 3;387(18):1649-1660. doi: 10.1056/NEJMoa2206660. N Engl J Med. 2022. PMID: 36322844 Free PMC article. Clinical Trial.
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.
Harker-Murray P, Mauz-Körholz C, Leblanc T, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger KJ, Amoroso L, Buffardi S, Rigaud C, Hoppe BS, Lisano J, Francis S, Sacchi M, Cole PD, Drachtman RA, Kelly KM, Daw S. Harker-Murray P, et al. Among authors: kelly km. Blood. 2023 Apr 27;141(17):2075-2084. doi: 10.1182/blood.2022017118. Blood. 2023. PMID: 36564047 Free PMC article. Clinical Trial.
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.
Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, Al Baghdadi T, Hines S, Everhart L, Highleyman L, Papadimitrakopoulou V, Neal JW, Waqar SN, Patel JD, Gray JE, Gandara DR, Kelly K, Herbst RS. Reckamp KL, et al. Among authors: kelly k. J Clin Oncol. 2022 Jul 20;40(21):2295-2306. doi: 10.1200/JCO.22.00912. Epub 2022 Jun 3. J Clin Oncol. 2022. PMID: 35658002 Free PMC article. Clinical Trial.
Classic Hodgkin lymphoma.
Kahn J, Dabaja B, Wu S, Kelly K, Berkahn L, Pavlovsky A, Sureda A, LaCasce A. Kahn J, et al. Among authors: kelly k. Hematol Oncol. 2023 Dec 1. doi: 10.1002/hon.3239. Online ahead of print. Hematol Oncol. 2023. PMID: 38037872 Review.
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K. Camidge DR, et al. Among authors: kelly k. J Clin Oncol. 2023 Feb 10;41(5):1105-1115. doi: 10.1200/JCO.22.00739. Epub 2022 Oct 26. J Clin Oncol. 2023. PMID: 36288547 Free PMC article. Clinical Trial.
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.
Spain L, Coulton A, Lobon I, Rowan A, Schnidrig D, Shepherd STC, Shum B, Byrne F, Goicoechea M, Piperni E, Au L, Edmonds K, Carlyle E, Hunter N, Renn A, Messiou C, Hughes P, Nobbs J, Foijer F, van den Bos H, Wardenaar R, Spierings DCJ, Spencer C, Schmitt AM, Tippu Z, Lingard K, Grostate L, Peat K, Kelly K, Sarker S, Vaughan S, Mangwende M, Terry L, Kelly D, Biano J, Murra A, Korteweg J, Lewis C, O'Flaherty M, Cattin AL, Emmerich M, Gerard CL, Pallikonda HA, Lynch J, Mason R, Rogiers A, Xu H, Huebner A, McGranahan N, Al Bakir M, Murai J, Naceur-Lombardelli C, Borg E, Mitchison M, Moore DA, Falzon M, Proctor I, Stamp GWH, Nye EL, Young K, Furness AJS, Pickering L, Stewart R, Mahadeva U, Green A, Larkin J, Litchfield K, Swanton C, Jamal-Hanjani M; PEACE Consortium; Turajlic S. Spain L, et al. Among authors: kelly k. Cancer Discov. 2023 Jun 2;13(6):1364-1385. doi: 10.1158/2159-8290.CD-22-1427. Cancer Discov. 2023. PMID: 36977461 Free PMC article.
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M. Daver NG, et al. Among authors: kelly kr. Blood. 2023 Mar 16;141(11):1265-1276. doi: 10.1182/blood.2022016362. Blood. 2023. PMID: 36265087 Free PMC article. Clinical Trial.
3,546 results